timothy sykes logo
ALLO Stock Jumps As Traders Target ALPHA3 Trial Catalyst Thumbnail
G Google News

ALLO Stock Jumps As Traders Target ALPHA3 Trial Catalyst

TIM SYKES•UPDATED APR. 13, 2026, 5:03 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Allogene Therapeutics Inc. stocks have been trading up by 7.35 percent after upbeat clinical data fueled renewed investor optimism.

Candlestick Chart

Live Update At 17:03:29 EDT: On Monday, April 13, 2026 Allogene Therapeutics Inc. stock [NASDAQ: ALLO] is trending up by 7.35%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ALLO has been trading like a classic biotech catalyst play. Over the past few weeks, Allogene Therapeutics stock climbed from about $2.10 on 2026/03/20 to a peak above $4.40 pre‑market on 2026/04/13 before closing at $3.06. That’s a huge round‑trip move, and it tells traders two things: there is strong interest around the ALPHA3 readout, and volatility in ALLO is very real.

Intraday on 2026/04/13, ALLO opened near $4.09, squeezed to $4.46, then unwound hard into the low $3s. The 5‑minute chart shows a classic morning spike and fade, followed by choppy action between $3.10 and $3.20. For active traders, that intraday range is opportunity, but it also demands tight risk control.

On the fundamentals, Allogene Therapeutics is still a clinical‑stage name burning cash. In Q4 2025, ALLO reported a net loss of about $38.8M, or roughly -$0.17 per share, driven by $28.6M in research and $13.8M in G&A. Return on equity is deeply negative, showing the business is far from profitability. The upside for traders is that ALLO holds roughly $250.2M in cash and short‑term investments and a strong current ratio of 7.9, giving the company runway to keep funding trials like ALPHA3.

Why Traders Are Watching ALLO’s ALPHA3 Catalyst

Traders are locked in on ALLO right now because the story is simple and powerful: one lead program, one clear catalyst. Allogene Therapeutics plans to present interim futility analysis data from its pivotal, randomized Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema‑cel) in first‑line consolidation for large B‑cell lymphoma on 2026/04/13. In biotech trading, a clean, binary‑style setup like that attracts momentum.

A futility analysis is a key milestone. It asks one blunt question: does the trial look so weak that it should be stopped early? For ALLO, a “not futile” outcome — meaning the trial continues as planned — can validate the company’s decision to push this allogeneic CAR‑T into a pivotal setting. It doesn’t prove success, but it signals the program is on track. Traders who specialize in catalysts understand that even a green light to continue can move a stock.

The recent ALLO chart reflects that anticipation. From late March into early April, Allogene Therapeutics climbed steadily from the low $2s into the mid‑$2s, then exploded above $4 on 2026/04/13 before fading. That spike lines up with traders front‑running the ALPHA3 news window. The intraday tape shows big liquidity pockets between $3.80 and $4.40 early, followed by an aggressive selloff once the morning euphoria cooled.

For short‑term traders, this is a textbook “event run‑up” pattern. ALLO’s high price‑to‑book ratio near 2.3, massive price‑to‑sales (effectively off the charts given minimal revenue), and heavy losses all say the same thing: this is a sentiment and data‑driven biotech, not a value play. Every tick now is about what the ALPHA3 futility update signals for cema‑cel and for Allogene Therapeutics as a whole.

More Breaking News

Conclusion

ALLO is trading where catalyst meets volatility. The upcoming interim futility analysis from the Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel in large B‑cell lymphoma is the center of gravity for Allogene Therapeutics right now. With cash of about $250.2M, negative earnings, and deep red return metrics, fundamental value arguments take a back seat. The main driver is whether ALPHA3 stays alive and looks clinically promising.

For traders, the tape already delivered a warning. The huge push above $4.40 followed by a collapse toward $3.00 on 2026/04/13 shows how crowded and emotional this trade can get. In such a volatile setup, discipline matters more than prediction. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. ALLO will likely stay on many watchlists as the market reacts to any new ALPHA3 color and reassesses the odds of long‑term success for cema‑cel.

The lesson from ALLO fits the core playbook this community has pushed for years. As Tim Sykes often reminds traders, “The key is not predicting the future, it’s preparing for different outcomes and cutting losses quickly when the market proves you wrong.” For Allogene Therapeutics, that means treating ALLO as a trading vehicle around clearly defined catalysts, not a blind long‑term bet. Study the chart, know the dates, define your risk, and let the price action around ALPHA3 do the talking.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading ALLO

Millionaire's
POV on ALLO

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”